Celebrating the 70 years of pyridostigmine on therapy of Myasthenia Gravis: historical aspects of the preliminary trials
Abstract Currently, pyridostigmine bromide is an indispensable anticholinesterase agent used worldwide to treat patients with Myasthenia Gravis (MG). However, pyridostigmine bromide was unsuccessful in its “pioneering trials” to treat a series of MG patients. There are important historical landmarks before pyridostigmine bromide becomes useful, safe and indispensable for MG therapy. After 70 years of these “pioneering trials”, this article reviews some historical aspects related to them, as well as other preliminary trials using pyridostigmine bromide as therapy for MG patients.
Guardado en:
| Autores principales: | , , , , , |
|---|---|
| Formato: | Digital revista |
| Idioma: | English |
| Publicado: |
Academia Brasileira de Neurologia - ABNEURO
2020
|
| Acceso en línea: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2020000300179 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|